Stay updated on Nivolumab + Cabozantinib in Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + Cabozantinib in Metastatic TNBC Clinical Trial page.

Latest updates to the Nivolumab + Cabozantinib in Metastatic TNBC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA new Locations section includes Massachusetts as a location, replacing the previous Massachusetts Locations heading; the page version is updated to v3.3.3 and the HHS Vulnerability Disclosure link in the footer was removed.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check36 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2. No visible changes to the study details, eligibility criteria, or trial status.SummaryDifference0.1%

- Check43 days agoChange DetectedThe funding-status banner at the top of the page header has been removed.SummaryDifference0.4%

- Check65 days agoChange DetectedNo substantive changes detected in core study information (inclusion criteria, outcomes, enrollment, locations, or investigators); the two screenshots show the same study details with only minor formatting differences. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check86 days agoChange DetectedCore content now includes an important government-operating-status notice and the site version is updated to v3.2.0, replacing the previous v3.1.0.SummaryDifference2%

- Check94 days agoChange DetectedThe page now lists Revision: v3.1.0 (replacing Revision: v3.0.2).SummaryDifference0.1%

Stay in the know with updates to Nivolumab + Cabozantinib in Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + Cabozantinib in Metastatic TNBC Clinical Trial page.